IBRAHIM TAHA ALDOSS M.D.
Prescription History 1861692485
Internal Medicine - Hematology in Duarte, CA

Active since July 21, 2007PECOS EnrolledAccepts Medicare Assignment
99.12/100
CMS Quality Rating
1500 E. DUARTE RD., DEPARTMENT OF HEMATOLOGY & HCT, DUARTE, CA 91010(626) 256-4673 Get Directions

NPPES record last updated: November 27, 2023. Verified against the NPPES registry weekly; last sync: October 25, 2026.

Record update history: Oct 28, 2020, Mar 7, 2018, Jul 3, 2017 and 1 more (4 updates tracked since 2016).

Medicare Part D Prescription History

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IBRAHIM TAHA ALDOSS M.D., an active Hematology specialist practicing in Duarte, CA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Revlimid, which accounts for 11 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.

1
Medication
11
Total Claims
11
30-Day Fills
Revlimid
Most Prescribed · 11 claims
View details
1 medication · 2024 Medicare Part D
Medicare Part D medications prescribed by IBRAHIM TAHA ALDOSS M.D. in 2024, with prescription volumes, average cost per fill, and CA state comparisons
Medication Prescriptions (2024)Rx (2024) Avg Cost per FillCost / Fill Vs. Other CA PrescribersVs. CA Avg
RevlimidLenalidomide11$14,061.54▼ below CA avg▼ Less than typical

About Revlimid: Lenalidomide is used to treat various types of cancers. Show more ▾

It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

In 2024, this provider wrote 11 Medicare prescriptions for Revlimid, about a third of the volume of the typical California prescriber of this medication (30.7). Medicare paid an average of $14,061.54 per fill, versus $17,406.67 statewide.

How often this provider prescribes it

This provider
11
CA average
30.7

This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference.

What Medicare paid per fill

This provider
$14,061.54
CA average
$17,406.67

This provider's average cost per fill is below the CA average for this medication.

11
30-Day Fills
standardized to 30-day supplies
308
Days of Medication
total across all patients in 2024
No medications match the current filters.
▲ More than typical≈ Typical▼ Less than typical= prescription volume vs the average CA prescriber of the same medication; volume reflects practice size as well as clinical preference.Green cost= below the CA average cost per fill.

About this data. The prescription history for IBRAHIM TAHA ALDOSS M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology prescribing approach at this Duarte, CA practice.

Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among CA prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.

About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.